UBS Initiates Coverage on Ensysce Biosciences, Inc. (ENSC) with Buy

Market Context

Ensysce Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $0.39 with a market capitalization of $3.4M. The stock has declined 82.3% over the past 52 weeks.

Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ensysce Biosciences, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Ensysce Biosciences, Inc.

Among the 6 most recent ratings: 6 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 12, 2026	UBS	Buy	N/A
Oct 20, 2026	Cantor Fitzgerald	Overweight	N/A
Sep 25, 2023	HC Wainwright & Co.	Buy	N/A
Jul 03, 2023	HC Wainwright & Co.	Buy	N/A
Nov 17, 2022	Lake Street	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ENSC Stock Page